Substances Co-ordination
Duplicated extension content project
Status: Complete
In the second quarter of 2025, concepts from the substance hierarchy that were used to model clinical drugs were collected from nine National Release Centers. These concepts and their terms were compared amongst each other and the international release. Of the 80 concepts that were found in multiple submissions, 30 were duplicate to current international concepts; almost 50 duplicates were found amongst two or more countries. However, four of these duplicates were rejected as organisms. Countries that had concepts with the earliest effective times were notified of the selection of their respective concept IDs. These concepts were promoted and were released into the international edition starting in the 1 August release and finishing in the 1 October 2025 release.
Single promotions project
Status: Complete
Substance concepts used to model clinical drugs and published only within a single extension were collected from nine NRCs for a total of 880 concepts. These were compared to the international release to check for duplication. Then, SNOMED International staff performed a high-level overview of immediately recognizable issues that could prevent concepts from being internationally applicable. NRCs were asked to further narrow down the list to only those applicable to the international edition of SNOMED CT. This reduced the number to 292, of which, 182 were promoted. These concepts were released into the international edition starting in the 1 September release and finishing in the 1 January 2026 release. Promotion of any further concepts shall resume via the usual Content Request Submission process.
Extensions identified with substances:
Extension | Point(s) of Contact |
|---|---|
Argentina | @ines otegui @Guillermo Reynoso |
Austria |
|
Australia | @Dion McMurtrie @Matt Cordell |
Canada | @Julie Boutin |
India |
|
Norway | @Hanne Fjeldstad Johansen |
Spain | @Marta Pavón Garrido |
UK | @Stuart Abbott (Unlicensed) |
Uruguay | @Betania Arispe (Unlicensed) @Rossana Occhiuzzi @Guillermo Reynoso |
US | @John Snyder @Nicholas McGraw |
Supporting Documents:
Document | Link & Details |
|---|---|
Combined Substances Worksheet | Combined List June 10th (requires access request) Updated to include more countries June 10th Tabs:
|
Review of Worksheet and Guidance for Extensions | |
Comments
Dear Monica,
We fully understand the importance of streamlining the process and avoiding duplication. However, the Spanish NRC submits monthly CRS requests specifically for new active substances needed to model newly created MP containing concepts representing medicines recently authorized at the EU level and commercialized in Spain. If we are unable to submit these requests, we are forced to create these concepts in our national extension and this approach increases the risk of duplication across extensions, exacerbating the problem we are trying to resolve.
Therefore, we kindly ask you to reconsider accepting CRS submissions for new active substances, provided we verify that these concepts are present neither in the International Edition nor in other national extensions. Each request is accompanied by the EMA Summary of Product Characteristics as supporting documentation.
Thank you for your understanding and consideration.
Marta Pavón Garrido
Head of Service
Spanish SNOMED CT National Release Center
Dear members of the DEUSG,
I sent a message using the SHARE function hereon but just to make sure you are in the know, I will repeat the message here.
In order to streamline the process: Please do not submit any CRS requests for substance content at this time whether for net new, or content for promotion, or change requests.
We have all the content from extensions and are continuing our review. Please complete review of any content you own. Following review, we will promote these concepts via the INFRA ticket system directly into the Authoring Platform. We track progress and will provide feedback in the google sheet and at the next meeting. -
Thanks for your co-operation and understanding.
Monica